A phase 1b/2 trial published in Nature Medicine has demonstrated that HRS-4642, a targeted KRAS-G12D inhibitor, significantly enhances treatment outcomes when combined with standard chemotherapy in patients with metastatic pancreatic cancer. The study marks a pivotal shift in managing a previously intractable oncogenic driver that has long limited therapeutic options for affected patients.
The trial enrolled patients harbouring KRAS G12D mutations—present in approximately 4–5% of pancreatic adenocarcinomas—and treated them with HRS-4642 alongside nab-paclitaxel and gemcitabine. Clinical response rates exceeded historical controls, suggesting that allele-specific inhibition paired with cytotoxic agents represents a viable precision oncology approach. These encouraging preliminary results warrant advancement to larger phase 2/3 randomised controlled trials to confirm efficacy and establish optimal dosing in this genetically defined population.
Read the full article on GMJ Newsroom.
Was this article helpful?
